Original Article
Prevalence of Monoclonal Gammopathy of Undetermined Significance
N Engl J Med 2006; 354:1362-1369March 30, 2006
- Abstract
Background
The prevalence of monoclonal gammopathy of undetermined significance (MGUS), a premalignant plasma-cell disorder, among persons 50 years of age or older has not been accurately determined. We used sensitive laboratory techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic area.
Methods
We identified all living residents of Olmsted County, Minnesota, as of January 1, 1995. We obtained serum that remained after the performance of routine clinical tests at Mayo Clinic or asked subjects for whom such serum was unavailable to provide a sample. Agarose-gel electrophoresis was performed on all serum samples, and any serum sample with a discrete band of monoclonal protein or thought to have a localized band was subjected to immunofixation.
Results
Serum samples were obtained from 21,463 of the 28,038 enumerated residents 50 years of age or older (76.6 percent). MGUS was identified in 694 (3.2 percent) of these persons. Age-adjusted rates were higher in men than in women (4.0 percent vs. 2.7 percent, P<0.001). The prevalence of MGUS was 5.3 percent among persons 70 years of age or older and 7.5 percent among those 85 years of age or older. The concentration of monoclonal immunoglobulin was less than 1.0 g per deciliter in 63.5 percent and at least 2.0 g per deciliter in only 4.5 percent of 694 persons. The concentration of uninvolved immunoglobulins was reduced in 27.7 percent of 447 persons tested, and 21.5 percent of 79 tested had a monoclonal urinary light chain.
Conclusions
Among residents of Olmsted County, Minnesota, MGUS was found in 3.2 percent of persons 50 years of age or older and 5.3 percent of persons 70 years of age or older.
Media in This Article
Figure 1
Prevalence of MGUS According to Age.Table 1
Prevalence of MGUS in Reported Studies.Article Activity
- Article
Although multiple myeloma is the prototypical monoclonal gammopathy, the most common plasma-cell disorder is the premalignant precursor of myeloma, monoclonal gammopathy of undetermined significance (MGUS). MGUS is defined by a monoclonal immunoglobulin concentration in serum of 3 g per deciliter or less; the absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the proliferation of monoclonal plasma cells; and a proportion of plasma cells in the bone marrow of 10 percent or less.1-3 In large referral centers, half the patients with a monoclonal gammopathy have MGUS, whereas only 15 to 20 percent have multiple myeloma.
MGUS is associated with a rate of progression to multiple myeloma or a related malignant condition of 1 percent per year.1,2 Since this rate does not decrease with time, a patient with MGUS requires follow-up indefinitely. A serum monoclonal protein concentration of at least 1.5 g per deciliter, a monoclonal immunoglobulin other than IgG, and an abnormal serum free light-chain ratio (kappa:lambda light chains) are the main risk factors for progression to a malignant condition.4 Twenty years after the diagnosis of MGUS, the risk of a malignant condition is 58 percent in patients with all three risk factors, 37 percent in patients with any two of the risk factors, 21 percent in patients with one risk factor, and 5 percent in patients with no risk factors. This classification identifies patients who are at highest risk for progression to multiple myeloma or a related malignant condition and who might benefit from an intervention that could prevent multiple myeloma.5
Opportunities to test preventive strategies are hampered by the underdiagnosis of MGUS in routine clinical practice. The coincidental finding of MGUS is not rare and is virtually never related to the patient's primary medical problem. Indeed, the frequency of monoclonal immunoglobulins in serum from a normal population has been reported to be 0.5 to 3.6 percent among patients seen in community practice6-8 or in hospitals9-11 (Table 1Table 1
Prevalence of MGUS in Reported Studies.). The true prevalence of MGUS has not been estimated accurately, however, because previous studies lacked a geographically defined population in which testing could be performed during a specified period. Furthermore, the screening methods used in many previous studies are less sensitive than current techniques. To overcome these limitations, we used sensitive laboratory procedures to determine the prevalence of MGUS in a large population in a well-defined geographic area.Methods
After the study was approved by the institutional review boards of the Mayo Foundation and the Olmsted Medical Center, we obtained a list of residents of Olmsted County, Minnesota, as of January 1, 1995, from the Rochester Epidemiology Project.15 For some residents who were included in this study, MGUS had been discovered during their routine clinical care. For the others, we obtained serum that remained unused after routine clinical tests in the Mayo Clinic central-processing laboratory, which receives all blood samples from Mayo Clinic outpatients and inpatients at its affiliated Saint Marys and Rochester Methodist hospitals in Rochester, Minnesota. In patients for whom three or more chemistry studies are ordered, an additional amount of blood is removed at initial phlebotomy; this practice permits physicians to order additional tests without performing another phlebotomy. These serum samples are held in the central-processing laboratory for six days and then discarded.
We developed a computerized system to track samples assayed by the central-processing laboratory, matched this information with demographic data in Mayo Clinic registration databases, and printed a daily listing of each sample from any resident of Olmsted County who was 50 years of age or older who had not already been incorporated into the study. These samples were retrieved on the sixth day after phlebotomy and frozen at ¡70°C. A letter, also approved by the institutional review boards, was then sent to each patient asking for permission to study the blood sample. The consent form enclosed in the letter was signed by the patient, witnessed, and returned to us. If the patient did not respond within 30 days, a second letter was sent, and if there was still no response, a third letter was sent 30 days later.
Any patient who had not responded to the three letters after six months and who returned to provide another blood sample was contacted again, as had been done initially, for permission to use the sample. If a patient had died, a letter was sent to the next of kin to obtain permission. Finally, all Olmsted County residents eligible for the study who had not been seen at Mayo Clinic during the collection period, with the exception of those who had died or had moved away, were sent a letter asking them to provide a serum specimen. Residents who obtained their medical care from Olmsted Medical Center were also contacted by letter and asked to provide a serum sample.
Laboratory Tests
Approximately four months after the collection of serum, when most of the subjects had replied to our letter, the samples from those who consented were thawed. Electrophoresis was performed on agarose gel (REP, Helena Laboratories). The agarose strip was inspected by a technician and by Dr. Kyle. Any serum with a discrete band or thought to have a localized band was subjected to immunofixation (Hydrasys and Hydragel, Sebia).16 If the patient did not give consent for use of the specimen, all patient-specific information, with the exception of sex and age group, was deleted to ensure anonymity, and the specimen was unmarked. These samples were tested in large batches, as prescribed by the institutional review board. MGUS was defined in accordance with previous definitions.1-3
Statistical Analysis
Although serum samples were collected over a period of several years, each subject was assessed only once. Because MGUS is a chronic condition, the first value obtained was presumed to represent the status of that subject as of January 1, 1995. Prevalence rates were calculated by dividing the number of persons with MGUS in each age and sex stratum by the number of subjects in that stratum for whom an assayed serum sample was available. Age-adjusted and overall age- and sex-adjusted prevalence rates were obtained by direct standardization to the total population of the United States that was 50 years of age or older in 2000.
The age- and sex-specific prevalence pattern was examined with a smoothed function of age, separately by sex, with the use of generalized-additive-model procedures for Poisson regression.17 The number of persons with MGUS was entered as the dependent variable, age as the independent variable, and the number of samples as an offset. This method has been illustrated previously with regard to trends in the prevalence of hip fractures.18 The study was designed, the data were gathered and analyzed, and the manuscript was written by all the authors.
Results
A total of 28,038 enumerated residents of Olmsted County were 50 years of age or older as of January 1, 1995. From January 1, 1995, to December 31, 2001, serum samples were obtained from 20,581 of these residents in the course of their routine clinical care. Permission to study the blood sample was obtained from 16,485 (79.1 percent) (Table 2Table 2
Results of Requests of Investigators to Study Serum Samples.). Of the families of deceased patients, 60.9 percent gave permission to use the sample.In addition, 229 patients who were known to have MGUS at the time of study entry and who would have been identified as part of the central-processing method intentionally were not retested. Among 220 participants, MGUS had been identified in 174 before the start of the study on January 1, 1995, and was identified in 46 by their physicians during the collection period. The nine remaining patients had monoclonal kappa or lambda light chains in the serum or urine.
By the end of the accrual period, 7228 residents still had not provided a sample. Letters requesting a sample were sent to 5117 residents, of whom 653 provided a sample. Letters were not sent to 2111 residents for the following reasons: 1609 had died, 262 had not given permission for their medical records to be reviewed,19 116 could not be contacted, 93 had moved outside Olmsted County, and 31 had a known MGUS but were not seen at Mayo Clinic during the sampling period (Table 2). Even though these 31 persons were known to have MGUS, they were excluded to avoid a biased estimate of prevalence.
Overall, 1455 patients declined to grant permission to use their samples and 2641 did not respond to our requests for permission. After all identification data except sex and age group were removed, electrophoresis was performed on the samples from these 4096 patients.
Prevalence
A monoclonal immunoglobulin was found in the serum of 371 of the 16,485 participants who had given permission (2.3 percent), 89 of the 4096 with blinded samples (2.2 percent), and 14 of the 653 who responded to our letters at the end of the accrual period (2.1 percent). In addition, samples from 229 participants who were known to have MGUS at study entry would have been analyzed. Thus, 694 of the 21,463 Olmsted County residents (3.2 percent) had MGUS.
MGUS was found in 350 of 9469 men, as compared with 344 of 11,994 women (3.7 percent vs. 2.9 percent, P<0.001) (Table 3Table 3
Prevalence of MGUS According to Age Group and Sex among Residents of Olmsted County, Minnesota.). Of the 20,072 Olmsted County residents whose race or ethnic group was known, 97.3 percent were white and 1.4 percent were Asian. Of the 605 patients with MGUS whose race or ethnic group was known, 99.3 percent were white.The overall prevalence of MGUS was 3.2 per 100 persons who were 50 years of age or older (95 percent confidence interval, 3.0 to 3.5) (Table 3). Age-adjusted rates were higher in men (4.0 per 100; 95 percent confidence interval, 3.5 to 4.4) than in women (2.7 per 100; 95 percent confidence interval, 2.4 to 3.0) (P<0.001). The rate among men was similar to that among women a decade older (Table 3). In both sexes, the prevalence increased with advancing age and was almost four times as high among persons 80 years of age or older as among those 50 to 59 years of age (Table 3). The prevalence leveled off after 85 years of age in men (Figure 1Figure 1
Prevalence of MGUS According to Age.) and after 90 years of age in women. In persons older than 85 years of age, the prevalence of MGUS was 8.9 percent in men and 7.0 percent in women (total, 7.5 percent). There was no significant difference in the concentration of the monoclonal protein among the age groups.The prevalence of MGUS decreased slightly throughout the data-collection period, from 4.4 percent in the first year to 3.2 percent through the last year of sample collection (P=0.41). Thus, patients who sought medical care frequently and, therefore, had blood samples analyzed earlier were at no greater risk for MGUS than the apparently healthier population who did not seek medical care regularly (and had blood samples analyzed later).
Laboratory Characteristics
The isotype of the monoclonal immunoglobulin was IgG in 68.9 percent of the 694 patients with MGUS, IgM in 17.2 percent, IgA in 10.8 percent, and biclonal in 3.0 percent. The serum light-chain type was kappa in 62.0 percent and lambda in 37.9 percent of these 694 patients. The monoclonal immunoglobulin concentration was less than 1.00 g per deciliter in 63.5 percent of patients, 1.00 to 1.49 g per deciliter in 16.6 percent, 1.50 to 1.99 g per deciliter in 15.4 percent, and at least 2.00 g per deciliter in 4.5 percent; it was too low to measure in 91 patients (13.1 percent). Individual values ranged from unmeasurable to 2.94 g per deciliter; the median was 0.5 g per deciliter, or 0.7 g per deciliter if the unmeasurable proteins were excluded. The concentration of uninvolved (normal, polyclonal, or background) immunoglobulins was reduced in 124 of the 447 patients whose immunoglobulin concentration was measured (27.7 percent). One of the two measured isotypes of polyclonal immunoglobulins was reduced in 21.9 percent of patients, and both were decreased in 5.8 percent. Urine from 79 subjects with MGUS was tested by means of immunofixation. A monoclonal kappa light chain (16.5 percent) or lambda light chain (5.0 percent) was found in 17 patients tested. Table 4Table 4
Characteristics of Patients with MGUS among Residents of Olmsted County, Minnesota. lists the laboratory features of patients in the nonblinded, blinded, and clinically recognized samples.Prevalence of MGUS in New Residents
During the seven-year accrual period, 2818 persons 50 years of age or older moved to Olmsted County and provided a blood sample during our collection process. Of these, 1778 (63.1 percent) gave permission to study their serum sample. They were not included in the prevalence estimate. The median age of this group was 65.9 years, and 47.4 percent were men. Sixty-five (3.7 percent) had MGUS. The median monoclonal immunoglobulin value was 0.6 g per deciliter, and the isotype was IgG in 69.2 percent. These values are similar to those for the long-time residents of Olmsted County.
Discussion
Although the term “monoclonal gammopathy of undetermined significance,” or “MGUS” was introduced more than 25 years ago1 and long-term studies of the prognosis have been reported,1,2,20 we are unaware of any previous studies that have established the prevalence of MGUS in a geographically defined population with the use of sensitive laboratory techniques. With the use of our computerized system, we obtained results from 76.6 percent of the enumerated population of Olmsted County that was 50 years of age or older, and MGUS was found in 3.2 percent. The prevalence of MGUS in this study of Olmsted County residents is approximately twice that reported in some other studies7,8 (Table 1). In particular, the 5.3 percent prevalence of MGUS among the Olmsted County residents 70 years or older was almost double that reported previously.7,8
Our results are almost fully representative of the entire population and are unlikely to be different had the total population been analyzed. Within the study cohort, the frequency of MGUS among subjects who gave permission to perform the serum studies was the same as that among subjects who did not give permission. The relatively high prevalence of MGUS in the general population in this study has implications for any screening programs or preventive strategies that are developed to reduce mortality from myeloma.
We found that the prevalence of MGUS increases with advancing age. In addition, we found that men have a higher frequency of MGUS than women; this finding corresponds to that in multiple myeloma, in which men account for almost 60 percent of patients.21 The association with age and sex was particularly notable in men 80 years of age or older, 8.3 percent of whom had MGUS. Knowledge of the age- and sex-specific prevalence rates of MGUS can influence patient care. Awareness of the frequency of MGUS in the elderly may limit the number of diagnostic tests to investigate the abnormality, because in most cases, the presence of a small monoclonal protein will be unrelated to the patient's medical problem. In fact, the presence of such a monoclonal immunoglobulin can be coincidental even among patients in whom a plasma-cell disorder is suspected. For example, elderly patients in whom systemic amyloidosis is diagnosed may have senile systemic amyloidosis and an unrelated MGUS, rather than a monoclonal protein associated with primary systemic amyloidosis. Nevertheless, all patients with MGUS must be monitored indefinitely for progression to a malignant condition.
The prevalence of MGUS increases with advancing age, but after adjustment for the concentration of the monoclonal protein, the annual risk of progression to myeloma or a related cancer is not affected by age or the duration of MGUS.2 Younger patients are more likely to have progression to cancer during their lifetimes simply because they are at risk for a longer time than are elderly patients.
The most common immunoglobulin type in MGUS identified in this study was IgG (more than two thirds of cases). This finding is similar to that in a French study,8 in which 68 percent of cases were of the IgG type. IgM MGUS was, however, found in 17 percent of our patients, 24 percent of patients in the French study, and only 8 percent in a Swedish study7; there is no apparent explanation for this discrepancy. The concentration of monoclonal protein in our study was small (median, 0.5 g per deciliter); 13.1 percent of patients had unmeasurable protein concentrations, and only 4.5 percent had a concentration of 2 g per deciliter or more.
In summary, this population-based study, which used sensitive laboratory techniques to detect monoclonal gammopathies, provides age- and sex-specific estimates of MGUS in a geographically defined population that is generally representative of the white population of the United States.15 Our results can form the basis of future screening programs and preventive strategies.
Supported in part by research grants (CA 62242 and CA 107476) from the National Cancer Institute.
No potential conflict of interest relevant to this article was reported.
We are indebted to Michelle Massey for performing the electrophoresis and immunofixation, to Tara Phelps for collecting and monitoring the samples, and to the Mayo Clinic Section of Scientific Publications for initial editing, proofreading, and reference verification.
Source Information
From the Divisions of Hematology (R.A.K., S.V.R., A.D.), Biostatistics (T.M.T., D.R.L., M.F.P., J.R.O.), Clinical Biochemistry and Immunology (J.A.K.), and Epidemiology (L.J.M.), Mayo Clinic, Rochester, Minn.
Address reprint requests to Dr. Kyle at the Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, or at kyle.robert@mayo.edu.
- References
References
1
Kyle RA . Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978;64:814-826
CrossRef | Web of Science | Medline2
Kyle RA ,Therneau TM ,Rajkumar SV , et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569
Full Text | Web of Science | Medline3
International Myeloma Working Group
CrossRef | Web of Science | Medline4
Rajkumar SV ,Kyle RA ,Therneau TM , et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-817
CrossRef | Web of Science | Medline5
Lust JA, Donovan KA. Chemoprevention: a new paradigm for managing patients with smoldering/indolent myeloma and high-risk MGUS. In: Kelloff GJ, Hawk ET, Sigman CC, eds. Cancer chemoprevention: strategies for cancer chemoprevention. Vol. 2. Totowa, N.J.: Humana Press, 2005:519-28.
6
Hallen J . Frequency of “abnormal“ serum globulins (M-components) in the aged. Acta Med Scand 1963;173:737-744
CrossRef | Web of Science | Medline7
Axelsson U ,Bachmann R ,Hallen J . Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand 1966;179:235-247
CrossRef | Web of Science | Medline8
Saleun JP ,Vicariot M ,Deroff P ,Morin JF . Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol 1982;35:63-68
CrossRef | Web of Science | Medline9
Vladutiu AO . Prevalence of M-proteins in serum of hospitalized patients: physicians' response to finding M-proteins in serum protein electrophoresis. Ann Clin Lab Sci 1987;17:157-161
Web of Science | Medline10
Malacrida V ,De Francesco D ,Banfi G ,Porta FA ,Riches PG . Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol 1987;40:793-797
CrossRef | Web of Science | Medline11
Aguzzi F ,Bergami MR ,Gasparro C ,Bellotti V ,Merlini G . Occurrence of monoclonal components in general practice: clinical implications. Eur J Haematol 1992;48:192-195
CrossRef | Web of Science | Medline12
Carrell RW ,Colls BM ,Murray JT . The significance of monoclonal gammopathy in a normal population. Aust N Z J Med 1971;1:398-401
CrossRef | Medline13
Kyle RA ,Finkelstein S ,Elveback LR ,Kurland LT . Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972;40:719-724
Web of Science | Medline14
Cohen HJ ,Crawford J ,Rao MK ,Pieper CF ,Currie MS . Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998;104:439-444[Erratum, Am J Med 1998;105:362.]
CrossRef | Web of Science | Medline15
Melton LJ III . History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-274
CrossRef | Web of Science | Medline16
Kyle RA, Katzmann JA, Lust JA, Dispenzieri A. Immunochemical characterization of immunoglobulins. In: Rose NR, Hamilton RG, Detrik B, eds. Manual of clinical laboratory immunology. 6th ed. Washington, D.C.: ASM Press, 2002:71-91.
17
Hastie TJ, Tibshirani RJ. Generalized additive models. London: Chapman & Hall, 1990.
18
Melton LJ III ,Therneau TM ,Larson DR . Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int 1998;8:68-74
CrossRef | Web of Science | Medline19
Melton LJ III . The threat to medical-records research. N Engl J Med 1997;337:1466-1470
Full Text | Web of Science | Medline20
Kyle RA ,Therneau TM ,Rajkumar SV ,Larson DR ,Plevak MF ,Melton LJ III . Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004;79:859-866
CrossRef | Web of Science | Medline21
Kyle RA ,Gertz MA ,Witzig TE , et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33
CrossRef | Web of Science | Medline
- Citing Articles (175)
Citing Articles
1
Morie A. Gertz. (2012) Immunoglobulin light chain amyloidosis: 2012 update on diagnosis, prognosis, and treatment. American Journal of Hematology 87:2, 183-189
CrossRef2
Anthony Mato, Tatyana Feldman, Joshua Richter, David S. Siegel, Andre Goy. (2012) Liquid Tumors in the Elderly. Clinics in Geriatric Medicine 28:1, 115-152
CrossRef3
Phandee Watanaboonyongcharoen, Thanyaphong Na Nakorn, Ponlapat Rojnuckarin, Panisinee Lawasut, Tanin Intragumtornchai. (2012) Prevalence of monoclonal gammopathy of undetermined significance in Thailand. International Journal of Hematology
CrossRef4
Daniel Spira, Katja Weisel, Harald Brodoefel, Maximilian Schulze, Sascha Kaufmann, Marius Horger. (2012) Can Whole-body Low-dose Multidetector CT Exclude the Presence of Myeloma Bone Disease in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)?. Academic Radiology 19:1, 89-94
CrossRef5
S. Vincent Rajkumar. (2012) Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. American Journal of Hematology 87:1, 78-88
CrossRef6
Pilar Brito-Zerón, Soledad Retamozo, Myriam Gandía, Miriam Akasbi, Marta Pérez-De-Lis, Candido Diaz-Lagares, Xavier Bosch, Albert Bové, Roberto Pérez-Alvarez, María-José Soto-Cárdenas, Antoni Sisó, Manuel Ramos-Casals. (2012) Monoclonal gammopathy related to Sjögren syndrome: A key marker of disease prognosis and outcomes. Journal of Autoimmunity
CrossRef7
A J Greenberg, C M Vachon, S V Rajkumar. (2011) Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia
CrossRef8
M. Chesi, P. L. Bergsagel. (2011) Many Multiple Myelomas: Making More of the Molecular Mayhem. Hematology 2011:1, 344-353
CrossRef9
Sumit Madan, Philip R. Greipp. 2011. Plasma Cell Disorders. , 287-306.
CrossRef10
Helen Marr, Gail L Jones, Graham H Jackson, Wendy Osborne. (2011) Diagnosis and management of haematological malignancies in older people. Reviews in Clinical Gerontology 21:04, 297-311
CrossRef11
Liliana Soltero, Hector Carbajal, Jiaqiong Xu, John McCarthy, Wadi N. Suki, A. Osama Gaber, Horacio E. Adrogué. (2011) Initial survival data of kidney transplant patients with pre-transplant monoclonal gammopathy. Clinical Transplantationno-no
CrossRef12
Sophie Voisin, Mohamed Hamidou, Armelle Lefrançois, Marianne Sigaud, Béatrice Mahé, Marc Trossaërt. (2011) Acquired von Willebrand Syndrome Associated With Monoclonal Gammopathy. Medicine 90:6, 404-411
CrossRef13
A. C. Ng, S. Khosla, N. Charatcharoenwitthaya, S. K. Kumar, S. J. Achenbach, M. F. Holets, L. K. McCready, L. J. Melton, R. A. Kyle, S. V. Rajkumar, M. T. Drake. (2011) Bone microstructural changes revealed by HRpQCT imaging and elevated DKK1 and MIP-1 levels in patients with monoclonal gammopathy of undetermined significance. Blood
CrossRef14
A. Torner, P. Dickman, A.-S. Duberg, S. Kristinsson, O. Landgren, M. Bjorkholm, A. Svensson. (2011) A Method to Visualize and Adjust for Selection Bias in Prevalent Cohort Studies. American Journal of Epidemiology 174:8, 969-976
CrossRef15
S. Mailankody, R. M. Pfeiffer, S. Y. Kristinsson, N. Korde, M. Bjorkholm, L. R. Goldin, I. Turesson, O. Landgren. (2011) Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 118:15, 4086-4092
CrossRef16
E. K. Lindqvist, L. R. Goldin, O. Landgren, C. Blimark, U.-H. Mellqvist, I. Turesson, A. Wahlin, M. Bjorkholm, S. Y. Kristinsson. (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood
CrossRef17
Dorota Rowczenio, Ahmet Dogan, Jason D. Theis, Julie A. Vrana, Helen J. Lachmann, Ashutosh D. Wechalekar, Janet A. Gilbertson, Toby Hunt, Simon D.J. Gibbs, Prayman T. Sattianayagam, Jenny H. Pinney, Philip N. Hawkins, Julian D. Gillmore. (2011) Amyloidogenicity and Clinical Phenotype Associated with Five Novel Mutations in Apolipoprotein A-I. The American Journal of Pathology 179:4, 1978-1987
CrossRef18
Robert Marc Zemble, Patricia A. Takach, Arnold I. Levinson. (2011) The Relationship Between Hypogammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance and Humoral Immunodeficiency: a Case Series. Journal of Clinical Immunology 31:5, 737-743
CrossRef19
Alessandra Galioto, Filippo Morando, Silvia Rosi, Mirko Schipilliti, Silvano Fasolato, Marta Magrin, Anna Chiara Frigo, Fausto Adami, Marta Cavallin, Giacomo Zanus, Mario Plebani, Antonietta Romano, Antonietta Sticca, Umberto Cillo, Angelo Gatta, Paolo Angeli. (2011) Monoclonal gammopathy after liver transplantation: a risk factor for long-term medical complications other than malignancies. Transplant Internationalno-no
CrossRef20
R. K. Wadhera, R. A. Kyle, D. R. Larson, A. Dispenzieri, S. Kumar, H. M. Lazarus, S. V. Rajkumar. (2011) Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 118:11, 2985-2987
CrossRef21
Z. Ouzzif, K. Doghmi, S. Bouhsain, A. Dami, S. El Machtani, S. Tellal, N. Messaoudi, M. Mikdame, A. El Maataoui. (2011) Monoclonal gammopathies in a Moroccan military hospital. Rheumatology International
CrossRef22
Hyun-Kyung Park, Kyoung-Ryul Lee, Young-Jin Kim, Han-Ik Cho, Jung Eun Kim, Ki Woong Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee. (2011) Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. American Journal of Hematology 86:9, 752-755
CrossRef23
James R. Berenson, Ori Yellin, Albert Quiery, James Brady, Ravi Patel, Siu-Fun Wong, Donald Colbourn, Donald Gravenor, Natasha Tiffany, H.K. Shamasunder, Benjamin Waterman, Kathryn Melamed, Eric Wirtschafter. (2011) A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma Myeloma and Leukemia 11:4, 336-341
CrossRef24
, Lewin Eisele, Jan Dürig, Andreas Hüttmann, Ulrich Dührsen, Roland Assert, Beate Bokhof, Raimund Erbel, Klaus Mann, Karl-Heinz Jöckel, Susanne Moebus. (2011) Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Annals of Hematology
CrossRef25
Sanjeev Sethi, Fernando C. Fervenza. (2011) Membranoproliferative Glomerulonephritis: Pathogenetic Heterogeneity and Proposal for a New Classification. Seminars in Nephrology 31:4, 341-348
CrossRef26
P Medd, S Littlewood, R Danby, R Malladi, R Clifford, D Wareham, K Jeffery, B Ferry, D Roberts, A Peniket, T Littlewood. (2011) Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation. Bone Marrow Transplantation 46:7, 993-999
CrossRef27
Brendan M. Weiss, Alex Minter, Jude Abadie, Robin Howard, Joao Ascencao, Geraldine P. Schechter, Michael Kuehl, Ola Landgren. (2011) Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. American Journal of Hematology 86:6, 475-478
CrossRef28
Manuel Ginarte. (2011) Comment on “Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis”. Journal of the American Academy of Dermatology 64:6, 1184
CrossRef29
N. Korde, S. Y. Kristinsson, O. Landgren. (2011) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 117:21, 5573-5581
CrossRef30
S. Vincent Rajkumar. (2011) Treatment of multiple myeloma. Nature Reviews Clinical Oncology 8:8, 479-491
CrossRef31
Shaji Kumar, S. Vincent Rajkumar. 2011. Multiple Myeloma: Molecular Biology, Diagnosis and Treatment. , 315-341.
CrossRef32
B Paiva, M Pérez-Andrés, M-B Vídriales, J Almeida, N de las Heras, M-V Mateos, L López-Corral, N C Gutiérrez, J Blanco, A Oriol, M T Hernández, F de Arriba, A G de Coca, M-J Terol, J de la Rubia, Y González, A Martín, A Sureda, M Schmidt-Hieber, A Schmitz, H E Johnsen, J-J Lahuerta, J Bladé, J F San-Miguel, A Orfao. (2011) Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia 25:4, 697-706
CrossRef33
Janel L. Chou, Makesha L. Sink. (2011) Corneal Crystals: A Precursor to Cancer. Optometry and Vision Science 88:4, E543-E547
CrossRef34
B. Paiva, M.-B. Vidriales, J. J. Perez, M.-C. Lopez-Berges, R. Garcia-Sanz, E. M. Ocio, N. de las Heras, R. Cuello, A. G. de Coca, E. Pardal, J. Alonso, M. Sierra, A. Barez, J. Hernandez, L. Suarez, J. Galende, M.-V. Mateos, J. F. San Miguel. (2011) The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 117:13, 3613-3616
CrossRef35
Henrik Gregersen, Mette Nørgaard, Marianne T. Severinsen, Malene C. Engebjerg, Paw Jensen, Henrik T. Sørensen. (2011) Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. European Journal of Haematology 86:2, 129-134
CrossRef36
Morie A. Gertz. (2011) Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 86:2, 180-186
CrossRef37
Feng Ge, Li-Jun Bi, Sheng-Ce Tao, Xu-dong Xu, Zhi-Ping Zhang, Kaio Kitazato, Xian-En Zhang. (2011) Proteomic analysis of multiple myeloma: Current status and future perspectives. PROTEOMICS - Clinical Applications 5:1-2, 30-37
CrossRef38
Stephanie Stringer, Kolitha Basnayake, Colin Hutchison, Paul Cockwell. (2011) Recent Advances in the Pathogenesis and Management of Cast Nephropathy (Myeloma Kidney). Bone Marrow Research 2011, 1-9
CrossRef39
Jianxiang Chi, Erica Ballabio, Xiao-He Chen, Rajko Kušec, Steve Taylor, Deborah Hay, Daniela Tramonti, Nigel J Saunders, Timothy Littlewood, Francesco Pezzella, Jacqueline Boultwood, James S Wainscoat, Christian SR Hatton, Charles H Lawrie. (2011) MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biology Direct 6:1, 23
CrossRef40
Neha Korde, Irina Maric. (2011) Myelomagenesis: Capturing Early Microenvironment Changes. Seminars in Hematology 48:1, 13-21
CrossRef41
S. Vincent Rajkumar. (2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 86:1, 57-65
CrossRef42
Macoura Gadji, Rhea Vallente, Ludger Klewes, Christiaan Righolt, Landon Wark, Narisorn Kongruttanachok, Hans Knecht, Sabine Mai. 2011. Nuclear Remodeling as a Mechanism for Genomic Instability in Cancer. , 77-126.
CrossRef43
Adriana Zingone, W. Michael Kuehl. (2011) Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma. Seminars in Hematology 48:1, 4-12
CrossRef44
Agnieszka Jurecka, Hanna Gregorek, Grazina Kleinotiene, Barbara Czartoryska, Anna Tylki-Szymanska. (2011) Gaucher disease and dysgammaglobulinemia: A report of 61 patients, including 18 with GD type III. Blood Cells, Molecules, and Diseases 46:1, 85-87
CrossRef45
Guner Hayri Ozsan, Angela Dispenzieri. (2011) Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias. Expert Review of Clinical Immunology 7:1, 65-73
CrossRef46
Goce Dimeski, Peter Wood. (2011) Sudden significant total protein concentration change: not an analytical problem. Journal of Clinical Laboratory Analysis 25:5, 330-331
CrossRef47
Tanjung A. Sumekar, Aneel A. Ashrani, Tri I. Winarni, Randi J. Hagerman. (2011) Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome. Case Reports in Genetics 2011, 1-5
CrossRef48
Odd Kildahl-Andersen, Klaus Murbræch, Hilde Skudal, Helge Stalsberg. (2011) En mann med vedvarende feber, nattesvette og høy senkningsreaksjon. Tidsskrift for Den norske legeforening 131:23, 2362-2365
CrossRef49
FE Davies, KC Anderson. 2011. Abnormalities in immunoglobulin synthesizing cells. , 451-469.
CrossRef50
A. J. Waxman, P. J. Mink, S. S. Devesa, W. F. Anderson, B. M. Weiss, S. Y. Kristinsson, K. A. McGlynn, O. Landgren. (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:25, 5501-5506
CrossRef51
Sham Mailankody, Esther Mena, Constance M. Yuan, Arun Balakumaran, W. Michael Kuehl, Ola Landgren. (2010) Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leukemia & Lymphoma 51:12, 2159-2170
CrossRef52
Robert B. Lorsbach. (2010) Update on the Diagnosis and Classification of the Plasma Cell Neoplasms. Surgical Pathology Clinics 3:4, 1061-1089
CrossRef53
Lydia Scarfò, Antonis Dagklis, Cristina Scielzo, Claudia Fazi, Paolo Ghia. (2010) CLL-like monoclonal B-cell lymphocytosis: Are we all bound to have it?. Seminars in Cancer Biology 20:6, 384-390
CrossRef54
Daniel Kim, Brian Kwok, Amir Steinberg. (2010) Simultaneous Acute Myeloid Leukemia and Multiple Myeloma Successfully Treated with Allogeneic Stem Cell Transplantation. Southern Medical Journal 103:12, 1246-1249
CrossRef55
Ulrike Bacher, Torsten Haferlach, Wolfgang Kern, Tamara Alpermann, Susanne Schnittger, Claudia Haferlach. (2010) Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. Cancer Genetics and Cytogenetics 203:2, 169-175
CrossRef56
Henrik Gregersen, Henrik Toft Sørensen, Malene Cramer Engebjerg, Paw Jensen, Marianne Tang Severinsen, Mette Nørgaard. (2010) Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. European Journal of Internal Medicine 21:6, 564-568
CrossRef57
O. Landgren. (2010) Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. Hematology 2010:1, 295-302
CrossRef58
Steven R. Schuster, Sundararajan Vincent Rajkumar, Angela Dispenzieri, William Morice, Alvaro Moreno Aspitia, Stephen Ansell, Robert Kyle, Joseph Mikhael. (2010) IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. American Journal of Hematology 85:11, 853-855
CrossRef59
Jesús San-Miguel, Joan Bladé. 2010. Multiple Myeloma. , 577-598.
CrossRef60
Francesca Prignano, Leonardo Pescitelli, Federica Ricceri, Angela Ermini, Torello Lotti. (2010) Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis. Journal of the American Academy of Dermatology 63:4, e84-e87
CrossRef61
S. V. Rajkumar, R. A. Kyle, F. K. Buadi. (2010) Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence. Mayo Clinic Proceedings 85:10, 945-948
CrossRef62
R. K. Wadhera, S. V. Rajkumar. (2010) Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Mayo Clinic Proceedings 85:10, 933-942
CrossRef63
G. Bianchi, R. A. Kyle, C. L. Colby, D. R. Larson, S. Kumar, J. A. Katzmann, A. Dispenzieri, T. M. Therneau, J. R. Cerhan, L. J. Melton, S. V. Rajkumar. (2010) Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood 116:12, 2019-2025
CrossRef64
CL Bi, WJ Chng. 2010. Molecular Genetics of Multiple Myeloma. .
CrossRef65
E. C. Heher, N. B. Goes, T. R. Spitzer, N. S. Raje, B. D. Humphreys, K. C. Anderson, P. G. Richardson. (2010) Kidney disease associated with plasma cell dyscrasias. Blood 116:9, 1397-1404
CrossRef66
Shaji Kumar, Teresa Kimlinger, William Morice. (2010) Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Practice & Research Clinical Haematology 23:3, 433-451
CrossRef67
Maurizio Zangari, Fenghuang Zhan, Guido Tricot. (2010) Bone and paraproteinemias. Current Opinion in Supportive and Palliative Care 4:3, 195-199
CrossRef68
Jonathan D. Godfrey, Tricia L. Brantner, Waleed Brinjikji, Kevin N. Christensen, Deanna L. Brogan, Carol T. Van Dyke, Brian D. Lahr, Joseph J. Larson, Alberto Rubio–Tapia, L. Joseph Melton, Alan R. Zinsmeister, Robert A. Kyle, Joseph A. Murray. (2010) Morbidity and Mortality Among Older Individuals With Undiagnosed Celiac Disease. Gastroenterology 139:3, 763-769
CrossRef69
O. Landgren, S. V. Rajkumar, R. M. Pfeiffer, R. A. Kyle, J. A. Katzmann, A. Dispenzieri, Q. Cai, L. R. Goldin, N. E. Caporaso, J. F. Fraumeni, W. J. Blot, L. B. Signorello. (2010) Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 116:7, 1056-1059
CrossRef70
Adam J. Waxman, Michael Kuehl, Arun Balakumaran, Brendan Weiss, Ola Landgren. (2010) Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma, Myeloma & Leukemia 10:4, 248-257
CrossRef71
Marzia Varettoni, Alessandro Corso, Federica Cocito, Silvia Mangiacavalli, Cristiana Pascutto, Patrizia Zappasodi, Gianmatteo Pica, Mario Lazzarino. (2010) Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance. Medicine 89:4, 211-216
CrossRef72
Jerry A. Katzmann. 2010. Identification of Biomarkers for Diagnosis of Amyloid Diseases: Quantitative Free Light-Chain Assays. , 689-697.
CrossRef73
R. H. Royer, J. Koshiol, T. R. Giambarresi, L. G. Vasquez, R. M. Pfeiffer, M. L. McMaster. (2010) Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation. Blood 115:22, 4464-4471
CrossRef74
Waleed Tamimi, Ahmad Alaskar, Mohammed Alassiri, Waleed Alsaeed, Saud A. Alarifi, Faris Q. Alenzi, Dunia Jawdat. (2010) Monoclonal gammopathy in a tertiary referral hospital. Clinical Biochemistry 43:9, 709-713
CrossRef75
Shaji Kumar. (2010) Treatment of newly diagnosed multiple myeloma: advances in current therapy. Medical Oncology 27:S1, 14-24
CrossRef76
R A Kyle, B G M Durie, S V Rajkumar, O Landgren, J Blade, G Merlini, N Kröger, H Einsele, D H Vesole, M Dimopoulos, J San Miguel, H Avet-Loiseau, R Hajek, W M Chen, K C Anderson, H Ludwig, P Sonneveld, S Pavlovsky, A Palumbo, P G Richardson, B Barlogie, P Greipp, R Vescio, I Turesson, J Westin, M Boccadoro. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:6, 1121-1127
CrossRef77
Angela Dispenzieri, Jerry A Katzmann, Robert A Kyle, Dirk R Larson, L Joseph Melton, Colin L Colby, Terry M Therneau, Raynell Clark, Shaji K Kumar, Arthur Bradwell, Rafael Fonseca, DF Jelinek, S Vincent Rajkumar. (2010) Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. The Lancet 375:9727, 1721-1728
CrossRef78
Frits van Rhee. (2010) Light-chain MGUS: implications for clinical practice. The Lancet 375:9727, 1670-1671
CrossRef79
James R. Berenson, Kenneth C. Anderson, Robert A. Audell, Ralph V. Boccia, Morton Coleman, Meletios A. Dimopoulos, Matthew T. Drake, Rafael Fonseca, Jean-Luc Harousseau, Douglas Joshua, Sagar Lonial, Ruben Niesvizky, Antonio Palumbo, G. David Roodman, Jesus F. San-Miguel, Seema Singhal, Donna M. Weber, Maurizio Zangari, Eric Wirtschafter, Ori Yellin, Robert A. Kyle. (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. British Journal of Haematologyno-no
CrossRef80
Robert A. Kyle, S. Vincent Rajkumar. (2010) Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Current Hematologic Malignancy Reports 5:2, 62-69
CrossRef81
Andrew J. Campbell, Linden Lyne, Philip J. Brown, Rosalind J. Launchbury, Paola Bignone, Jianxiang Chi, Giovanna Roncador, Charles H. Lawrie, Kevin C. Gatter, Rajko Kusec, Alison H. Banham. (2010) Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. British Journal of Haematology 149:2, 221-230
CrossRef82
Brendan M Weiss, W Michael Kuehl. (2010) Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Review of Hematology 3:2, 165-174
CrossRef83
Elizabeth C Lorenz, Sanjeev Sethi, Nelson Leung, Angela Dispenzieri, Fernando C Fervenza, Fernando G Cosio. (2010) Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney International 77:8, 721-728
CrossRef84
Alexander Ademokun, Yu-Chang Wu, Deborah Dunn-Walters. (2010) The ageing B cell population: Composition and function. Biogerontology 11:2, 125-137
CrossRef85
Marinos C. Dalakas. (2010) Pathogenesis and Treatment of Anti-MAG Neuropathy. Current Treatment Options in Neurology 12:2, 71-83
CrossRef86
Béatrice Bouvard, Mathieu Royer, Daniel Chappard, Maurice Audran, Emmanuel Hoppé, Erick Legrand. (2010) Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis. Joint Bone Spine 77:2, 120-124
CrossRef87
J. Hillengaß, H. Goldschmidt. (2010) Multiples Myelom. Der Onkologe 16:3, 225-231
CrossRef88
Carmen Stanganelli, Jorge Arbelbide, Dorotea Beatriz Fantl, Claudia Corrado, Irma Slavutsky. (2010) DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Annals of Hematology 89:2, 191-199
CrossRef89
Neil E. Caporaso, Gerald E. Marti, Ola Landgren, Elizabeth Azzato, J. Brice Weinberg, Lynn Goldin, Tait Shanafelt. (2010) Monoclonal B cell lymphocytosis: Clinical and population perspectives. Cytometry Part B: Clinical Cytometry 78B:S1, S115-S119
CrossRef90
Mario Ojeda-Uribe, Claudine Caron, Nathalie Itzhar-Baikian, Agathe Debliquis. (2010) Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance. American Journal of HematologyNA-NA
CrossRef91
Neil E. Caporaso, Gerald E. Marti, Robert F. Vogt, Youn K. Shim, Dan Middleton, Ola Landgren. (2010) Evolution of a precursor. Cytometry Part B: Clinical Cytometry 78B:1, 1-3
CrossRef92
M. Perez-Andres, B. Paiva, W. G. Nieto, A. Caraux, A. Schmitz, J. Almeida, R. F. Vogt, G. E. Marti, A. C. Rawstron, M. C. Van Zelm, J. J. M. Van Dongen, H. E. Johnsen, B. Klein, A. Orfao, . (2010) Human peripheral blood B-cell compartments: A crossroad in B-cell traffic. Cytometry Part B: Clinical Cytometry 78B:S1, S47-S60
CrossRef93
Mary L. McMaster, Ola Landgren. (2010) Prevalence, clinical aspects, and natural history of IgM MGUS. Cytometry Part B: Clinical Cytometry 78B:S1, S91-S97
CrossRef94
S V Rajkumar, N M-B Killmann. (2009) Spotlight review series on multiple myeloma. Leukemia 23:1r, R1-R2
CrossRef95
H.-T. Tsai, N. E. Caporaso, R. A. Kyle, J. A. Katzmann, A. Dispenzieri, R. B. Hayes, G. E. Marti, M. Albitar, P. Ghia, S. V. Rajkumar, O. Landgren. (2009) Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 114:24, 4928-4932
CrossRef96
Roy Freeman. (2009) Not all neuropathy in diabetes is of diabetic etiology: Differential diagnosis of diabetic neuropathy. Current Diabetes Reports 9:6, 423-431
CrossRef97
Ross B Fulton, Steven M Varga. (2009) Effects of aging on the adaptive immune response to respiratory virus infections. Aging Health 5:6, 775-787
CrossRef98
Colin A. Hutchison, Kolitha Basnayake, Paul Cockwell. (2009) Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nature Reviews Nephrology 5:11, 621-628
CrossRef99
Sumit Madan, Philip R. Greipp. (2009) The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Reviews 23:6, 257-265
CrossRef100
S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, A. Zullo, B. Franco, K. C. Anderson, N. C. Munshi. (2009) Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 114:15, 3276-3284
CrossRef101
O Landgren, B M Weiss. (2009) Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23:10, 1691-1697
CrossRef102
Jenny Bird, Judith Behrens, Jan Westin, Ingemar Turesson, Mark Drayson, Robert Beetham, Shirley D’Sa, Richard Soutar, Anders Waage, Nina Gulbrandsen, Henrik Gregersen, Eric Low, . (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology 147:1, 22-42
CrossRef103
R. S. Go, L. M. Doyle. (2009) A monoclonal gammopathy in search of clinical significance: 57 years later. Blood 114:11, 2355-2356
CrossRef104
M Dimopoulos, E Terpos, R L Comenzo, P Tosi, M Beksac, O Sezer, D Siegel, H Lokhorst, S Kumar, S V Rajkumar, R Niesvizky, L A Moulopoulos, B G M Durie. (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 23:9, 1545-1556
CrossRef105
J. P. Bida, R. A. Kyle, T. M. Therneau, L. J. Melton, M. F. Plevak, D. R. Larson, A. Dispenzieri, J. A. Katzmann, S. V. Rajkumar. (2009) Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients. Mayo Clinic Proceedings 84:8, 685-693
CrossRef106
H. T. Lynch, S. D. Thome. (2009) Familial multiple myeloma. Blood 114:4, 749-750
CrossRef107
O. Landgren, S. Y. Kristinsson, L. R. Goldin, N. E. Caporaso, C. Blimark, U.-H. Mellqvist, A. Wahlin, M. Bjorkholm, I. Turesson. (2009) Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114:4, 791-795
CrossRef108
C. M. Vachon, R. A. Kyle, T. M. Therneau, B. J. Foreman, D. R. Larson, C. L. Colby, T. K. Phelps, A. Dispenzieri, S. K. Kumar, J. A. Katzmann, S. V. Rajkumar. (2009) Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 114:4, 785-790
CrossRef109
O. Landgren, R. A. Kyle, J. A. Hoppin, L. E. Beane Freeman, J. R. Cerhan, J. A. Katzmann, S. V. Rajkumar, M. C. Alavanja. (2009) Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 113:25, 6386-6391
CrossRef110
Ryan B. Turner, Harley A. Haynes, Scott R. Granter, Danielle M. Miller. (2009) Acquired cutis laxa following urticarial vasculitis associated with IgA myeloma. Journal of the American Academy of Dermatology 60:6, 1052-1057
CrossRef111
J. Blade, L. Rosinol, M. T. Cibeira. (2009) Are all myelomas preceded by MGUS?. Blood 113:22, 5370-5370
CrossRef112
B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, W. M. Kuehl. (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:22, 5418-5422
CrossRef113
O. Landgren, R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, R. Hoover, S. V. Rajkumar. (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:22, 5412-5417
CrossRef114
Luisa María Villar Guimerans, Juan José Rodríguez Molina, Cándido Juárez Rubio. (2009) Análisis interlaboratorio de parámetros inmunoquímicos, paraproteínas y bandas oligoclonales. Informe técnico del IV Taller de Inmunoquímica de la Sociedad Española de Inmunología. Inmunología 28:2, 79-95
CrossRef115
Claire-Anne Siegrist, Richard Aspinall. (2009) B-cell responses to vaccination at the extremes of age. Nature Reviews Immunology 9:3, 185-194
CrossRef116
BoGun Jang, Youngil Koh, Jeong-Wook Seo. (2009) Immunohistochemical classification of amyloid deposits in surgical pathology. Basic and Applied Pathology 2:1, 1-8
CrossRef117
Kate L. Gibson, Yu-Chang Wu, Yvonne Barnett, Orla Duggan, Robert Vaughan, Elli Kondeatis, Bengt-Olof Nilsson, Anders Wikby, David Kipling, Deborah K. Dunn-Walters. (2009) B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 8:1, 18-25
CrossRef118
Mary L. McMaster, Sigurdur Y. Kristinsson, Ingemar Turesson, Magnus Björkholm, Ola Landgren. (2009) Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. Clinical Lymphoma, Myeloma & Leukemia 9:1, 19-22
CrossRef119
Peter G Czarnecki, Donna J Lager, Nelson Leung, Angela Dispenzieri, Fernando G Cosio, Fernando C Fervenza. (2009) Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney International 75:4, 420-427
CrossRef120
Vivek Roy. (2009) Artifactual Laboratory Abnormalities in Patients with Paraproteinemia. Southern Medical Journal 102:2, 167-170
CrossRef121
J. J. Pinzone, B. M. Hall, N. K. Thudi, M. Vonau, Y.-W. Qiang, T. J. Rosol, J. D. Shaughnessy. (2009) The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113:3, 517-525
CrossRef122
S. Vincent Rajkumar. (2009) Multiple Myeloma. Current Problems in Cancer 33:1, 7-64
CrossRef123
D. P. Steensma. (2009) The changing classification of myelodysplastic syndromes: what's in a name?. Hematology 2009:1, 645-655
CrossRef124
Cees G. Schaar, Saskia le Cessie, Simone Snijder, Paul F. H. Franck, Pierre W. Wijermans, Cisca Ong, Hanneke Kluin-Nelemans. (2009) Long-term follow-up of a population based cohort with monoclonal proteinaemia. British Journal of Haematology 144:2, 176-184
CrossRef125
Saša A. Živković, David Lacomis, Suzanne Lentzsch. (2009) Paraproteinemic neuropathy. Leukemia & Lymphoma 50:9, 1422-1433
CrossRef126
A. D. Wechalekar, H. J. Lachmann, H. J. B. Goodman, A. Bradwell, P. N. Hawkins, J. D. Gillmore. (2008) AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 112:10, 4009-4016
CrossRef127
S. Y. Kristinsson, T. R. Fears, G. Gridley, I. Turesson, U.-H. Mellqvist, M. Bjorkholm, O. Landgren. (2008) Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112:9, 3582-3586
CrossRef128
Andreas J. Steck, Adam Czaplinski, Susanne Renaud. (2008) Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: Treatment update. Neurotherapeutics 5:4, 528-534
CrossRef129
J Bladé, L Rosiñol, M T Cibeira, C F de Larrea. (2008) Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22:9, 1651-1657
CrossRef130
Jo Caers, Isabelle Vande broek, Hendrik De Raeve, Lucienne Michaux, Fabienne Trullemans, Rik Schots, Ben Van Camp, Karin Vanderkerken. (2008) Multiple myeloma - an update on diagnosis and treatment. European Journal of Haematology
CrossRef131
Agostino Ognibene, Maria S. Graziani, Anna Caldini, Alessandro Terreni, Gabriella Righetti, Maria C. Varagnolo, Ada Campanella, Marinella Martelli, Rita Mancini, Paolo Rizzotti, Mario Plebani, Marco Mori, Giovanni Gaspari, Roberto Motta, Gianni Galli, Massimiliano Fabris, Gianni Messeri. (2008) Computer-assisted detection of monoclonal components: results from the multicenter study for the evaluation of CASPER (Computer Assisted Serum Protein Electrophoresis Recognizer) algorithm. Clinical Chemistry and Laboratory Medicine 46:8, 1183-1188
CrossRef132
Saad P. Shaheen, Sameer S. Talwalkar, L. Jeffrey Medeiros. (2008) Multiple Myeloma and Immunosecretory Disorders. Advances in Anatomic Pathology 15:4, 196-210
CrossRef133
Jessica Pepe, Maria Teresa Petrucci, Maria Lucia Mascia, Sara Piemonte, Valeria Fassino, Elisabetta Romagnoli, Salvatore Minisola. (2008) The Effects of Alendronate Treatment in Osteoporotic Patients Affected by Monoclonal Gammopathy of Undetermined Significance. Calcified Tissue International 82:6, 418-426
CrossRef134
T. Aprahamian, Y. Takemura, D. Goukassian, K. Walsh. (2008) Ageing is associated with diminished apoptotic cell clearance in vivo. Clinical & Experimental Immunology 152:3, 448-455
CrossRef135
M.E. González García, C. Fernández Álvarez, V. Robles Marinas, A.J. González Huerta, M.I. Arias Miranda, A.P. González Rodríguez, J. García Casas, J. Moris de La Tassa, J. Fernández García. (2008) Serie de 618 casos de gammapatías monoclonales de significado indeterminado (GMSI): factores predictivos de desaparición del componente monoclonal o de evolución a gammapatías malignas. Revista Clínica Española 208:6, 288-294
CrossRef136
Anne-Sophie Moreau, Yasmine Sebti, Alain Duhamel, Aldo M. Roccaro, Valérie Coiteux, Thomas Gastinne, Gaëlle Le Friec, Nicholas Burwick, Laurence Amiot, Allen W. Ho, Stephanie Poulain, Bernadette Hennache, Zachary R. Hunter, Jean-Paul Dessaint, Irene M. Ghobrial, Steven P. Treon, Thierry Facon, Emmanuel Zorn, Xavier Leleu. (2008) Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. European Journal of Haematology 80:6, 503-509
CrossRef137
M. Fost, T. A. Out, F. A. Wilde, E. P. M. Tjin, S. T. Pals, M. H. J. Oers, R. G. Boot, J. F. M. G. Aerts, M. Maas, S. Dahl, C. E. M. Hollak. (2008) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Annals of Hematology 87:6, 439-449
CrossRef138
Colin A Hutchison, Paul Cockwell, Steven Harding, Graham P Mead, Arthur R Bradwell, Anthony H Barnett. (2008) Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease?. Expert Opinion on Therapeutic Targets 12:6, 667-676
CrossRef139
J.A. Páramo Fernández. (2008) Gammapatías monoclonales de significado incierto. Revista Clínica Española 208:6, 267-268
CrossRef140
Shinichi Nishi, Bassam Alchi, Nofumi Imai, Fumitake Gejyo. (2008) New advances in renal amyloidosis. Clinical and Experimental Nephrology 12:2, 93-101
CrossRef141
M.T. Agyei-Frempong, E. Nkansah, G. Bedu-Addo, K. Opare-Sem. (2008) Incidence of Paraproteinaemia in Hyperproteinaemic Patients Visiting the Chemical Pathology Unit of the Komfo Anokye Teaching Hospital. Journal of Medical Sciences(Faisalabad) 8:4, 378-383
CrossRef142
R. A. Kyle, S. V. Rajkumar. (2008) Multiple myeloma. Blood 111:6, 2962-2972
CrossRef143
Marta Chesi, Davide F. Robbiani, Michael Sebag, Wee Joo Chng, Maurizio Affer, Rodger Tiedemann, Riccardo Valdez, Stephen E. Palmer, Stephanie S. Haas, A. Keith Stewart, Rafael Fonseca, Richard Kremer, Giorgio Cattoretti, P. Leif Bergsagel. (2008) AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell 13:2, 167-180
CrossRef144
K C Anderson, R A Kyle, S V Rajkumar, A K Stewart, D Weber, P Richardson. (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22:2, 231-239
CrossRef145
Charlene Hoffman-Snyder, Benn E. Smith. (2008) Neuromuscular Disorders Associated with Paraproteinemia. Physical Medicine and Rehabilitation Clinics of North America 19:1, 61-79
CrossRef146
M. Jinushi, M. Vanneman, N. C. Munshi, Y.-T. Tai, R. H. Prabhala, J. Ritz, D. Neuberg, K. C. Anderson, D. R. Carrasco, G. Dranoff. (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences 105:4, 1285-1290
CrossRef147
H. Kaufmann, J. Ackermann, V. Odelga, V. Sagaster, T. Nösslinger, M. Pfeilstöcker, A. Keck, H. Ludwig, H. Gisslinger, J. Drach. (2008) Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS. European Journal of Clinical Investigation 38:1, 53-60
CrossRef148
Marinos C. Dalakas. 2008. Autoimmune peripheral neuropathies. , 977-994.
CrossRef149
Robert A. Kyle, Angela Dispenzieri. 2008. Monoclonal gammopathies. , 1167-1180.
CrossRef150
W.J. Chng, O. Glebov, P.L. Bergsagel, W.M. Kuehl. (2007) Genetic events in the pathogenesis of multiple myeloma. Best Practice & Research Clinical Haematology 20:4, 571-596
CrossRef151
Robert A. Kyle, S. Vincent Rajkumar. (2007) Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Hematology/Oncology Clinics of North America 21:6, 1093-1113
CrossRef152
Robert A. Kyle, S. Vincent Rajkumar. (2007) Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. British Journal of Haematology 139:5, 730-743
CrossRef153
Pierre Lozeron, David Adams. (2007) Monoclonal gammopathy and neuropathy. Current Opinion in Internal Medicine 6:6, 631-636
CrossRef154
S. Vincent Rajkumar, Antonio Palumbo. (2007) Management of Newly Diagnosed Myeloma. Hematology/Oncology Clinics of North America 21:6, 1141-1156
CrossRef155
Ola Landgren, Robert A. Kyle. (2007) Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. British Journal of Haematology 139:5, 717-723
CrossRef156
Robert A. Kyle, S. Vincent Rajkumar. (2007) Epidemiology of the plasma-cell disorders. Best Practice & Research Clinical Haematology 20:4, 637-664
CrossRef157
Robert F. Vogt, Gerald E. Marti. (2007) Overview of monoclonal gammopathies of undetermined significance. British Journal of Haematology 139:5, 687-689
CrossRef158
M. J. Molina-Garrido, C. Guillén-Ponce, A. Mora, M. Guirado-Risueño, M. A. Molina, M. J. Molina, A. Carrato. (2007) Deposition-associated diseases related with a monoclonal compound. Clinical and Translational Oncology 9:12, 777-783
CrossRef159
O. Decaux, P. Rodon, A. Ruelland, L. Estepa, R. Leblay, B. Grosbois. (2007) Épidémiologie descriptive des gammapathies monoclonales. Expérience d'un centre hospitalier général et d'un service de médecine interne de centre hospitalier et universitaire. La Revue de Médecine Interne 28:10, 670-676
CrossRef160
B. Grosbois. (2007) Gammapathie monoclonale et myélome multiple: quelles nouveautés? quelles perspectives?. La Revue de Médecine Interne 28:10, 667-669
CrossRef161
Robert A. Kyle, Vincent S. Rajkumar. 2007. Monoclonal Gammopathy of Undetermined Significance. , 95-114.
CrossRef162
Derralynn Hughes, Maria Domenica Cappellini, Marc Berger, Jan Van Droogenbroeck, Maaike de Fost, Dragana Janic, Theodore Marinakis, Hanna Rosenbaum, Jesús Villarubia, Elena Zhukovskaya, Carla Hollak. (2007) Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. British Journal of Haematology 138:6, 676-686
CrossRef163
S. Vincent Rajkumar, Martha Q. Lacy, Robert A. Kyle. (2007) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Reviews 21:5, 255-265
CrossRef164
K. L. Morris, J. R. Tate, D. Gill, G. Kennedy, J. Wellwood, P. Marlton, R. Bird, A. K. Mills, P. Mollee. (2007) Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Internal Medicine Journal 37:7, 456-463
CrossRef165
L. Rosinol, M. T. Cibeira, S. Montoto, M. Rozman, J. Esteve, X. Filella, J. Blade. (2007) Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. Mayo Clinic Proceedings 82:4, 428-434
CrossRef166
A. Victor Hoffbrand, Terry J. Hamblin. (2007) Is “leukemia” an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia?. Leukemia Research 31:3, 273-275
CrossRef167
Francesco A. Piazza, Carmela Gurrieri, Livio Trentin, Gianpietro Semenzato. (2007) Towards a new age in the treatment of multiple myeloma. Annals of Hematology 86:3, 159-172
CrossRef168
Dominik D. Alexander, Pamela J. Mink, Hans-Olov Adami, Philip Cole, Jack S. Mandel, Martin M. Oken, Dimitrios Trichopoulos. (2007) Multiple myeloma: A review of the epidemiologic literature. International Journal of Cancer 120:S12, 40-61
CrossRef169
Bladé, Joan, . (2006) Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine 355:26, 2765-2770
Full Text170
Hans Link, Yu-Min Huang. (2006) Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness. Journal of Neuroimmunology 180:1-2, 17-28
CrossRef171
Henrik Gregersen, Paw Jensen, Mette Gislum, Birgit Jorgensen, Henrik Toft Sorensen, Mette Norgaard. (2006) Fracture risk in patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology 135:1, 62-67
CrossRef172
Saša A Živković. (2006) Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Review of Neurotherapeutics 6:9, 1267-1274
CrossRef173
Robert A. Kyle, S. Vincent Rajkumar. (2006) Monoclonal gammopathy of undetermined significance. British Journal of Haematology 134:6, 573-589
CrossRef174
(2006) Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine 354:26, 2832-2832
Full Text175
S. V. Rajkumar, A. Dispenzieri, R. A. Kyle. (2006) Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment. Mayo Clinic Proceedings 81:5, 693-703
CrossRef
- Letters
